|
Malignant neoplasm of breast
|
0.310 |
Biomarker
|
disease |
BEFREE |
In this study we used the breast cancer cell lines MCF7 and MCF7-hCNT1 (stably transfected with hCNT1) to determine whether hCNT1 expression can complement hENT1 functional loss in the cytotoxicity and transcriptomic response triggered by nucleoside analogues.
|
18053967 |
2008 |
|
Breast Carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
In this study we used the breast cancer cell lines MCF7 and MCF7-hCNT1 (stably transfected with hCNT1) to determine whether hCNT1 expression can complement hENT1 functional loss in the cytotoxicity and transcriptomic response triggered by nucleoside analogues.
|
18053967 |
2008 |
|
Malignant neoplasm of breast
|
0.310 |
Biomarker
|
disease |
CTD_human |
These results indicate that the expression of the high-affinity concentrative nucleoside transporter hCNT1 has a prognostic value in determining disease-free survival and risk of relapse in breast cancer patients undergoing surgery followed by cyclophosphamide-methotrexate-5-fluorouracil chemotherapy.
|
16837820 |
2006 |
|
Breast Carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
These results indicate that the expression of the high-affinity concentrative nucleoside transporter hCNT1 has a prognostic value in determining disease-free survival and risk of relapse in breast cancer patients undergoing surgery followed by cyclophosphamide-methotrexate-5-fluorouracil chemotherapy.
|
16837820 |
2006 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.
|
16837820 |
2006 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.
|
16837820 |
2006 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.
|
16837820 |
2006 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Mean blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Interethnic analyses of blood pressure loci in populations of East Asian and European descent.
|
30487518 |
2018 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Interethnic analyses of blood pressure loci in populations of East Asian and European descent.
|
30487518 |
2018 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
There was also a significantly higher transcript level of SLC28A1 in tumors with regional lymph nodes affected by metastasis.
|
23934321 |
2013 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Moreover, this study also shows that restoration of hCNT1 expression is able to reduce tumor growth in a mouse model of pancreatic adenocarcinoma.
|
23722537 |
2013 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In addition to supporting a putative tumor suppressor role for hCNT1, our findings identify hCNT1 as a potential candidate to render drug-resistant pancreatic cancer cells amenable to chemotherapy.
|
21343396 |
2011 |
|
Leukopenia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
For SLC28A1 rs3825876 (G>A), AA patients have a higher risk of neutropenia than GA and GG patients (P=0.02, hazard ratio: 1.51, 95% confidence interval: 1.06-2.16).
|
30889042 |
2019 |
|
Neutropenia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
For SLC28A1 rs3825876 (G>A), AA patients have a higher risk of neutropenia than GA and GG patients (P=0.02, hazard ratio: 1.51, 95% confidence interval: 1.06-2.16).
|
30889042 |
2019 |
|
Pancreatic Neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, these data point out to MUC4 and hCNT1 as potential targets to ameliorate the response of pancreatic tumors to gemcitabine treatment.
|
22580602 |
2013 |
|
Adenocarcinoma of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, and in accordance with our in vitro data, we found that MUC4 expression was conversely correlated to that of hCNT1 in tissues from patients with pancreatic adenocarcinoma.
|
22580602 |
2013 |
|
Adenocarcinoma of pancreas
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Moreover, this study also shows that restoration of hCNT1 expression is able to reduce tumor growth in a mouse model of pancreatic adenocarcinoma.
|
23722537 |
2013 |
|
Pancreatic Neoplasm
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Compared with normal pancreas and pancreatic ductal epithelial cells, hCNT1 expression was frequently reduced in pancreatic tumors and tumor cell lines.
|
21343396 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In NSCLC patients, CDA+435 C>T variants were associated with response (p=0.026) and time to progression (p=0.016) and SLC28A1+1561 G>A variants were associated with neutropenia (p=0.030) and thrombocytopenia nadir (p=0.037).
|
18538445 |
2009 |
|
Leukopenia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In NSCLC patients, CDA+435 C>T variants were associated with response (p=0.026) and time to progression (p=0.016) and SLC28A1+1561 G>A variants were associated with neutropenia (p=0.030) and thrombocytopenia nadir (p=0.037).
|
18538445 |
2009 |
|
Neutropenia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In NSCLC patients, CDA+435 C>T variants were associated with response (p=0.026) and time to progression (p=0.016) and SLC28A1+1561 G>A variants were associated with neutropenia (p=0.030) and thrombocytopenia nadir (p=0.037).
|
18538445 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In NSCLC and normal tissues expression of hENT1 and hCNT1 ranged from completely negative to high.
|
18600541 |
2008 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
LHGDN |
In uterine cervix tumors, the loss of expression of hCNT1 was significantly associated with the adenocarcinoma subtype.
|
15386342 |
2004 |